Al's Comment:

 

 This is an experimental drug - which in this poster from ASCO shows a small trial of 8 patients with newly diagnosed glioblastoma, unmethylated MGMT, who did pretty good compared to what we have seen previously with Temozolomide.  This opens a new option for unmethylated MGMT patients, and perhaps eventually in combinations for all gbm (and DIPG and brain met patients.

 

---

Posted on: 06/01/2020

Phase 2a study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K / mTOR inhibitor GDC-0084 given to glioblastoma (GBM) patients with unmethylated MGMT promotor status 

 

---

Click HERE to return to brain tumor news headlines.